AI Article Synopsis
- The study investigates the influence of probiotics on intestinal failure-associated liver disease (IFALD) in patients receiving home parenteral nutrition (HPN) or intravenous fluids (HIVFs).
- A total of 282 patients were reviewed, revealing that 27.7% used probiotics, with lower IFALD prevalence in this group (35.9% vs. 54.4% without probiotics).
- The findings highlight that small bowel length (10-90 cm) and HPN use significantly impacted IFALD, while probiotic use did not show a notable difference in prevalence.
Article Abstract
Background: It has been hypothesized that dysbiosis plays a significant role in the pathogenesis of intestinal failure-associated liver disease (IFALD). Therefore, we aimed to investigate the effect of probiotics on IFALD in patients receiving parenteral support, namely home parenteral nutrition (HPN) and home intravenous fluids (HIVFs).
Methods: We retrospectively reviewed charts of patients with intestinal failure who received HPN or HIVF for >2 weeks at our tertiary center between January 2005 and August 2016. We excluded patients <18 years of age, patients with other causes of liver disease, patients who used probiotics for <30 days, patients with <6 months' follow-up, and those who had long-term antibiotic use (>30 days). Bivariable and multivariable logistic regression analyses were used in this study.
Results: A total of 282 patients who received parenteral support were included. Eighty-five percent of our sample received PN. A total of 78 (27.7%) patients used probiotics. The prevalence of IFALD in patients who used probiotics was 35.9% vs 54.4% in patients who did not use probiotics, P = .005. In multivariable analysis, only small-bowel length of 10-90 cm and HPN use showed a significant impact on IFALD, odds ratio (OR) = 4.394 (95% confidence interval [CI], 1.635-11.814; P = .003) and OR = 4.502 (95% CI 1.412-14.351; P = .011), respectively.
Conclusion: Our study revealed that the prevalence of IFALD was comparable among the probiotic users and nonusers. Only small bowel length of 1090 cm and HPN use showed a significant impact on IFALD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ncp.10437 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prediction of chronic severe intestinal failure-associated liver disease by current criteria in adults: A descriptive cohort study.
JPEN J Parenter Enteral Nutr
December 2024
Intestinal Failure Unit, Salford Royal, NHS Foundation Trust, Salford, UK.
Introduction: Intestinal failure-associated liver disease covers a spectrum of conditions from mild to end-stage disease. Currently, there are 9 diagnostic criteria divided to four categories: cholestasis, steatosis, fibrosis, and unclassified. Our aim was to evaluate the application of these criteria to patients with chronic severe liver disease in patients with intestinal failure.
View Article and Find Full Text PDFIntestinal failure-associated liver disease model: a reduced phytosterol intravenous lipid emulsion prevents liver injury.
Pediatr Res
November 2024
Vascular Biology Program and the Department of Surgery, Boston Children's Hospital, Boston, MA, USA.
Background: Long-term parenteral nutrition in children often results in intestinal failure-associated liver disease (IFALD). Phytosterols are plant steroids in vegetable oil-based intravenous lipid emulsions (ILEs) that are associated with IFALD. We investigated whether a phytosterol-depleted soybean oil ILE, compared to standard soybean oil ILE, prevented hepatotoxicity in a murine IFALD model.
View Article and Find Full Text PDFFavorable inhibitory effect of clodronate on hepatic steatosis in short bowel syndrome model rats.
Pediatr Surg Int
November 2024
Department of Pediatric Surgery, Medical and Dental Area, Research and Education Assembly, Research Field in Medical and Health Sciences, Kagoshima University, 8-35-1, Sakuragaoka, Kagoshima, 890-8520, Japan.
Article Synopsis
- This study looked at how clodronate, which affects vesicular nucleotide transport, impacts liver inflammation linked to intestinal failure in rats with short bowel syndrome.
- The researchers used a rat model that involved feeding them through a vein and surgically removing most of their small intestine, then giving them different doses of clodronate.
- Results showed that high doses of clodronate reduced liver fat and inflammation in the rats, suggesting potential benefits for patients with similar conditions related to intestinal failure.
Dipeptidyl peptidase IV inhibitors reduce hepatic fibrosis and lipid accumulation in rat intestinal failure-associated liver disease models.
Pediatr Surg Int
October 2024
Department of Pediatric Surgery, Tokyo Women's Medical University, 8‑1 Kawada‑Cho, Shinjuku‑Ku, Tokyo, 162‑8666, Japan.
Purpose: This study aimed to investigate the effectiveness of dipeptidyl peptidase IV inhibitors (DPP4-I) against liver damage, especially fibrosis and lipid accumulation, in a rat intestinal failure-associated liver disease (IFALD) model.
Methods: SD rats were divided into two groups: the Control (n = 7; normal saline + IFALD model) and DPP4-I (n = 7; DPP4-I + IFALD model; short bowel syndrome (SBS) + total parenteral nutrition) groups. All rats were euthanized 21 days postoperatively to obtain tissue samples.
Long Rectal Cuff and Remnant Mesorectum Are Major Preventable Causes of Ileal Pouch Failure.
Dis Colon Rectum
January 2025
Department of Surgery, Inflammatory Bowel Disease Center, NYU Langone Health, New York, New York.
Background: Long rectal cuff (>2 cm) and remnant mesorectum are known causes of pouch dysfunction because of obstructive defecation as well as pelvic sepsis after prolonged obstruction.
Objective: The aim of this study was to report the rates and management of patients who underwent redo IPAA because of pouch failure associated with a retained mesorectum and long rectal cuff.
Design: This is a retrospective study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!